Find Ozenoxacin manufacturers, exporters & distributors on PharmaCompass

Ozenoxacin

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

5 API Suppliers, 3 USDMF, 1 JDMF, 1 EU WC, 1 KDMF, 3 NDC API, 4 Listed Suppliers, $ API Reference Price

5 API Suppliers
3 USDMF
1 JDMF
1 EU WC
1 KDMF
3 NDC API
4 Listed Suppliers
$ API Reference Price

INTERMEDIATES

4 Intermediates Suppliers

4 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

1 FDF Dossiers, 1 FDA Orange Book

1 FDF Dossiers
1 FDA Orange Book

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 1 NEWS #PharmaBuzz

media
1 DATA COMPILATION #PharmaFlow
1 NEWS #PharmaBuzz

MARKET PLACE

4 APIs, 1 FDF Dossiers

marketPlace
4 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Patents

patents
2 US Patents

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

API

FDF

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 245765-41-7, Xepi, T-3912, T 3912, 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxoquinoline-3-carboxylic acid, Gf-001001-00

Molecular Formula

C₂₁H₂₁N₃O₃

Molecular Weight

363.4 g/mol

InChI Key

XPIJWUTXQAGSLK-UHFFFAOYSA-N

FDA UNII

V0LH498RFO

To date, ozenoxacin has been used in trials studying the treatment of impetigo. As of December 11, 2017 the FDA approved Ferrer Internacional S.A.'s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by *Staphylococccus aureus* or *Streptococcus pyogenes* in adult and pediatric patients 2 months of age and older. Despite being a common and highly contagious bacerial skin infection that affects millions of children and adults in the United States each year, ozenoxacin cream is a novel, non-fluorinated quinolone that has demonstrated safe and effective therapy in both the adult and pediatric population.

Ozenoxacin is a Quinolone Antimicrobial.

1 2D Structure

Ozenoxacin

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxoquinoline-3-carboxylic acid

2.1.2 InChI

InChI=1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27)

2.1.3 InChI Key

XPIJWUTXQAGSLK-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=CC(=CN=C1NC)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)C

2.2 Other Identifiers

2.2.1 UNII

V0LH498RFO

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)-3-pyridinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic Acid

2. Ozanex

3. Xepi

2.3.2 Depositor-Supplied Synonyms

1. 245765-41-7

2. Xepi

3. T-3912

4. T 3912

5. 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxoquinoline-3-carboxylic Acid

6. Gf-001001-00

7. V0lh498rfo

8. 1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)pyridin-3-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

9. Ozenoxacin Cream

10. Ozenoxacin [inn]

11. Ozenoxacin [inn:jan]

12. Unii-v0lh498rfo

13. Ozadub

14. Xepi (tn)

15. Ozenoxacin [mi]

16. Ozenoxacin; T-3912

17. Ozenoxacin [jan]

18. Ozenoxacin [usan]

19. Ozenoxacin [who-dd]

20. Ozenoxacin (jan/usan/inn)

21. Schembl1711829

22. Chembl3990047

23. Ozenoxacin [orange Book]

24. Gtpl10841

25. Dtxsid00947446

26. Chebi:136050

27. Bcp16621

28. Ex-a2693

29. Vja76541

30. Who 8788

31. Zinc1483896

32. S6582

33. Akos032947315

34. At18754

35. Db12924

36. Sb16801

37. Ncgc00532517-01

38. Bs-16742

39. Da-31712

40. Hy-14957

41. Ozenoxacin 100 Microg/ml In Acetonitrile

42. Cs-0003657

43. Ft-0701296

44. D09544

45. Q17125399

46. Gf-001001-00; M-5120; T-3912; Gf-00100100;t3912;t 3912

47. 1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)-3-pyridinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic Acid

48. 3-quinolinecarboxylic Acid, 1-cyclopropyl-1,4-dihydro-8-methyl-7-(5-methyl-6-(methylamino)-3-pyridinyl)-4-oxo-

2.4 Create Date

2006-10-25

3 Chemical and Physical Properties

Molecular Formula	C₂₁H₂₁N₃O₃
Molecular Weight	363.4 g/mol
XLogP3	4.1
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	4
Exact Mass	363.15829154 g/mol
Monoisotopic Mass	363.15829154 g/mol
Topological Polar Surface Area	82.5 Å²
Heavy Atom Count	27
Formal Charge	0
Complexity	645
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Ozenoxacin cream is indicated for the topical treatment of impetigo caused by *Staphylococcus aureus* or *Streptococcus pyogenes* in patients aged 2 months of age and older.

FDA Label

Treatment of impetigo

5 Pharmacology and Biochemistry

5.1 Pharmacology

Although the exposure response relationship for ozenoxacin after it has been applied topically has not yet been studied, a formal relationship is unlikely because systemic exposure of ozenoxacin following its topical application has been measured to be negligible.

5.2 MeSH Pharmacological Classification

Anti-Bacterial Agents

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)

Topoisomerase Inhibitors

Compounds that inhibit the activity of DNA TOPOISOMERASES. (See all compounds classified as Topoisomerase Inhibitors.)

5.3 FDA Pharmacological Classification

5.3.1 Active Moiety

OZENOXACIN

5.3.2 FDA UNII

V0LH498RFO

5.3.3 Pharmacological Classes

Quinolones [CS]; Quinolone Antimicrobial [EPC]

5.4 ATC Code

D - Dermatologicals

D06 - Antibiotics and chemotherapeutics for dermatological use

D06A - Antibiotics for topical use

D06AX - Other antibiotics for topical use

D06AX14 - Ozenoxacin

5.5 Absorption, Distribution and Excretion

Absorption

Four studies were performed in which varying strengths of ozenoxacin cream, up to 2% (twice the concentration of the marketed formulation), were administered to 110 patients. Three of the studies examined systemic absorption in healthy subjects and in subjects having impetigo. The studies were performed with either single or repeated application of up to 1 g ozenoxacin cream to intact or abraded skin (up to 200 cm squared surface area). No systemic absorption was seen in 84 of 86 subjects, and negligible systemic absorption was seen at the level of detection (0.489 ng/mL) in 2 subjects.

Route of Elimination

Studies regarding elimination and excretion have not yet been investigated in humans due to the negligible systemic absorption observed in clinical studies.

Volume of Distribution

Ozenoxacin undergoes negligible systemic absorption after its topical administration. Subsequently, since negligible systemic absorption of ozenoxacin was observed in clinical studies, tissue distribution has not been investigated in humans either.

Clearance

Ozenoxacin undergoes negligible systemic absorption after its topical administration.

5.6 Metabolism/Metabolites

Studies have demonstrated that ozenoxacin is not metabolized in the presence of fresh human skin discs and is minimally metabolized in human hepatocytes.

5.7 Mechanism of Action

Ozenoxacin is a quinolone antibiotic drug. And, like most quinolones, ozenoxacin predominately executes its mechanism of action by entering into bacterial cells and acting to inhibit the bacterial DNA replication enzymes DNA gyrase A and topoisomerase IV. As DNA gyrase A and topoisomerase IV are essential to bacterial DNA replication activities including supercoiling, supercoil relaxation, chromosomal condensation, chromosomal decatenation and more, their inhibition is the principal action of ozenoxacin's mechanism and it has been demonstrated to be bactericidal against *S. aureus* and *S. pyogenes* organisms.

API SUPPLIERS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

01

Metrochem API Private Limited

India

Antibody Engineering

Not Confirmed

Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Contact Supplier

India

Virtual Booth

Digital Content

Ozenoxacin

About the Company :

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product ...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer

02

Shandong Chenghui Shuangda Pharmace...

China

CPhI China

Attending

Shuangda Pharmaceutical has a world-class first-class production line, having GMP, FDA and other regulatory certifications.

Contact Supplier

China

Virtual Booth

Digital Content

Ozenoxacin

About the Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. is specialized in R&D and production of APIs and advanced intermediates. With 22 years of production experience,the company has ...

Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. is specialized in R&D and production of APIs and advanced intermediates. With 22 years of production experience,the company has 6 workshops and 9 production lines which has 100t/month production capacity.The company is committed to maintain the standards with continuous improvements to the current standards throughout the product lifecycle.The main products include local anesthetic drugs, antiviral drugs, cardiovascular and cerebrovascular drugs, antitumor drugs, gastrointestinal drugs, diabetic drugs, veterinary drugs, and CDMO products.

03

Maithri Drugs

India

Antibody Engineering

Not Confirmed

04

Optimus Pharma

India

Antibody Engineering

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

[{"dataSource":"API Export","activeIngredients":"OZENOXACIN","year":"2021","qtr":"Q1","strtotime":1614623400,"product":"PHARMACEUTICAL RAW MATERIAL OZENOXACIN","address":"MALVA,UNIT NO.108,PATANWALA ESTATE,L.B.S. MARG, GHATKOPAR WEST,","city":"MUMBAI ,MAHARASHTRA","supplier":"PRECISE GROUP","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"SOUTHEAST BANK LIMITED","customerCountry":"BANGLADESH","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"7475","totalValueFC":"36989","currency":"USD","unitRateINR":538569.80000000005,"date":"02-Mar-2021","totalValueINR":"2692849","totalValueInUsd":"36989","indian_port":"BOMBAY AIR","hs_no":"29334900","bill_no":"9042127","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"MALVA,UNIT NO.108,PATANWALA ESTATE,L.B.S. MARG, GHATKOPAR WEST,, MUMBAI ,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"OZENOXACIN","year":"2021","qtr":"Q2","strtotime":1619807400,"product":"PHARMACEUTICAL RAW MATERIAL: OZENOXACIN","address":"MALVA,UNIT NO.108,PATANWALA ESTATE,L.B.S. MARG, GHATKOPAR WEST,","city":"MUMBAI ,MAHARASHTRA","supplier":"PRECISE GROUP","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"TO AL-ARAFAH ISLAMI BANK LTD.","customerCountry":"BANGLADESH","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"7372.8","totalValueFC":"72521.1","currency":"USD","unitRateINR":531212.30000000005,"date":"01-May-2021","totalValueINR":"5312123","totalValueInUsd":"72521.1","indian_port":"BOMBAY AIR","hs_no":"29334900","bill_no":"1506462","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"MALVA,UNIT NO.108,PATANWALA ESTATE,L.B.S. MARG, GHATKOPAR WEST,, MUMBAI ,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1692210600,"product":"OZENOXACIN","address":"PLOT NO.C-24 MNS HOUSE INDUSTRIAL ESTATE SANATH NAGAR","city":"Hyderabad","supplier":"MAITHRI DRUGS PRIVATE ","supplierCountry":"INDIA","foreign_port":"NA","customer":"TO","customerCountry":"CHINA","quantity":"0.30","actualQuantity":"300","unit":"GMS","unitRateFc":"13.4","totalValueFC":"3959.6","currency":"USD","unitRateINR":1093.3333319999999,"date":"17-Aug-2023","totalValueINR":"327999.9996","totalValueInUsd":"3959.6","indian_port":"HYDERABAD ICD","hs_no":"29333990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD ICD","supplierAddress":"PLOT NO.C-24 MNS HOUSE INDUSTRIAL ESTATE SANATH NAGAR, Hyderabad","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1712514600,"product":"OZENOXACIN IN-HOUSE BATCH NO.118002022024 MFG.DT-FEB-2024 RETEST DT-JUL-2026","address":"209, JHALAWAR,,PATANWALA ESTATE,","city":"MUMBAI,MAHARASHTRA","supplier":"PRECISE BIO PHARMA PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"KATHMANDU","customer":"TO THE ORDER OF","customerCountry":"NEPAL","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"320000","totalValueFC":"383.2","currency":"INR","unitRateINR":320000,"date":"08-Apr-2024","totalValueINR":"32000","totalValueInUsd":"383.2","indian_port":"Raxaul","hs_no":"29334900","bill_no":"8984862","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"NEPAL","selfForZScoreResived":"Pharma Grade","supplierPort":"Raxaul","supplierAddress":"209, JHALAWAR,,PATANWALA ESTATE,, MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1723919400,"product":"OZENOXACIN","address":"FLAT NO.302, BHANU ENCLAVE","city":"HYDERABAD.AP","supplier":"METROCHEM API PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"KATHMANDU","customer":"ELIXIR LIFE SCIENCE PVT.LTD","customerCountry":"NEPAL","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"250000","totalValueFC":"1490.3","currency":"INR","unitRateINR":250000,"date":"18-Aug-2024","totalValueINR":"125000","totalValueInUsd":"1490.3","indian_port":"Raxaul","hs_no":"29322090","bill_no":"3296228","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"NEPAL","selfForZScoreResived":"Pharma Grade","supplierPort":"Raxaul","supplierAddress":"FLAT NO.302, BHANU ENCLAVE, HYDERABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1724869800,"product":"OZENOXACIN","address":"FLAT NO.302, BHANU ENCLAVE","city":"HYDERABAD.AP","supplier":"METROCHEM API PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"BIRGUNJ","customer":"MARUTI PHARMA PVT.LTD","customerCountry":"NEPAL","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"230000","totalValueFC":"2742.1","currency":"INR","unitRateINR":230000,"date":"29-Aug-2024","totalValueINR":"230000","totalValueInUsd":"2742.1","indian_port":"Raxaul","hs_no":"29322090","bill_no":"3589626","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"NEPAL","selfForZScoreResived":"Pharma Grade","supplierPort":"Raxaul","supplierAddress":"FLAT NO.302, BHANU ENCLAVE, HYDERABAD.AP","customerAddress":""}]